FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3132085485> ?p ?o ?g. }

• W3132085485 endingPage "11" @default.
• W3132085485 startingPage "PD1" @default.
• W3132085485 abstract "Abstract Background: In the PAKT study, addition of the oral AKT inhibitor capivasertib to 1st-line paclitaxel therapy for metastatic TNBC resulted in significantly longer progression-free survival (PFS; primary endpoint; Schmid, J Clin Oncol 2020). The stratified PFS hazard ratio was 0.74 (95% CI, 0.50-1.08; one-sided P=0.06; predefined significance level of 0.10, one-sided; median PFS 5.9 vs 4.2 months with capivasertib vs placebo). Overall survival (OS) results were immature at the primary analysis with 53% of events but suggested long OS with capivasertib (HR, 0.61; 95% CI, 0.37-0.99; two-sided P=0.04). Here we report final results. Methods: This double-blind, placebo-controlled, randomised phase II trial, recruited women with untreated, metastatic TNBC. Total of 140 patients were randomly assigned (1:1) to paclitaxel 90mg/m2 (days 1, 8, 15) with either capivasertib (400mg twice daily) or placebo (days 2-5, 9-12, 16-19) every 28 days until disease progression or unacceptable toxicity. The primary endpoint was PFS. Secondary endpoints included OS in the ITT population and in patients with and without PIK3CA/AKT1/PTEN-alterations. Results: With a median F/U of 40.0 months, median OS was longer in the capivasertib arm (19.1 vs 13.5 months, stratified HR 0.70, 95% CI 0.47-1.05, p=0.085). In contrast to the earlier analysis, no meaningful differences were seen in terms of benefit with capivasertib between patients with or without alterations of PIK3CA/AKT1/PTEN. Median OS numerically favoured capivasertib vs placebo both in the PIK3CA/AKT1/PTEN-altered (stratified HR 0.58, 95% CI 0.21-1.58, p=0.290) and PIK3CA/AKT1/PTEN non-altered subgroup (stratified HR 0.74, 95% CI 0.47-1.18, p=0.207). The safety profile of capivasertib plus paclitaxel was unchanged. Conclusions: Final OS results show a numerical trend favouring capivasertib; effects were observed regardless of PIK3CA/AKT1/PTEN alterations. Consistent with the previously observed PFS benefit, these findings support further evaluation of first-line Capivasertib plus paclitaxel for metastatic TNBC in the ongoing Capitello290 randomised phase III trial in patients with and without PIK3CA/AKT1/PTEN alterations. Citation Format: Peter Schmid, Jacinta Abraham, Stephen Chan, Adrian Murray Brunt, Gia Nemsadze, Richard D Baird, Yeon Hee Park, Peter Hall, Timothy Perren, Robert C Stein, László Mangel, Jean-Marc Ferrero, Melissa Phillips, John Conibear, Javier Cortes, Andrew Foxley, Elza de Bruin, Robert McEwen, Myria Nikolaou, Daniel Stetson, Brian Dougherty, Aaron Prendergast, Max McLaughlin-Callan, Matthew Burgess, Cheryl Lawrence, Hayley Cartwright, Kelly Mousa, Nicholas Turner, Duncan Wheatley. Mature survival update of the double-blind placebo-controlled randomised phase II PAKT trial of first-line capivasertib plus paclitaxel for metastatic triple-negative breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PD1-11." @default.
• W3132085485 created "2021-03-01" @default.
• W3132085485 creator A5007089296 @default.
• W3132085485 creator A5009167161 @default.
• W3132085485 creator A5012810093 @default.
• W3132085485 creator A5014159829 @default.
• W3132085485 creator A5014243045 @default.
• W3132085485 creator A5015824949 @default.
• W3132085485 creator A5019696786 @default.
• W3132085485 creator A5031415556 @default.
• W3132085485 creator A5031499770 @default.
• W3132085485 creator A5032686530 @default.
• W3132085485 creator A5037122637 @default.
• W3132085485 creator A5038092151 @default.
• W3132085485 creator A5043150762 @default.
• W3132085485 creator A5046151881 @default.
• W3132085485 creator A5051629490 @default.
• W3132085485 creator A5053495453 @default.
• W3132085485 creator A5056505692 @default.
• W3132085485 creator A5057566178 @default.
• W3132085485 creator A5058756575 @default.
• W3132085485 creator A5065435228 @default.
• W3132085485 creator A5069401956 @default.
• W3132085485 creator A5074364623 @default.
• W3132085485 creator A5075498749 @default.
• W3132085485 creator A5076440721 @default.
• W3132085485 creator A5082719961 @default.
• W3132085485 creator A5085819010 @default.
• W3132085485 creator A5087646089 @default.
• W3132085485 creator A5089861374 @default.
• W3132085485 creator A5090226538 @default.
• W3132085485 date "2021-02-15" @default.
• W3132085485 modified "2023-10-18" @default.
• W3132085485 title "Abstract PD1-11: Mature survival update of the double-blind placebo-controlled randomised phase II PAKT trial of first-line capivasertib plus paclitaxel for metastatic triple-negative breast cancer" @default.
• W3132085485 doi "https://doi.org/10.1158/1538-7445.sabcs20-pd1-11" @default.
• W3132085485 hasPublicationYear "2021" @default.
• W3132085485 type Work @default.
• W3132085485 sameAs 3132085485 @default.
• W3132085485 citedByCount "3" @default.
• W3132085485 countsByYear W31320854852022 @default.
• W3132085485 countsByYear W31320854852023 @default.
• W3132085485 crossrefType "journal-article" @default.
• W3132085485 hasAuthorship W3132085485A5007089296 @default.
• W3132085485 hasAuthorship W3132085485A5009167161 @default.
• W3132085485 hasAuthorship W3132085485A5012810093 @default.
• W3132085485 hasAuthorship W3132085485A5014159829 @default.
• W3132085485 hasAuthorship W3132085485A5014243045 @default.
• W3132085485 hasAuthorship W3132085485A5015824949 @default.
• W3132085485 hasAuthorship W3132085485A5019696786 @default.
• W3132085485 hasAuthorship W3132085485A5031415556 @default.
• W3132085485 hasAuthorship W3132085485A5031499770 @default.
• W3132085485 hasAuthorship W3132085485A5032686530 @default.
• W3132085485 hasAuthorship W3132085485A5037122637 @default.
• W3132085485 hasAuthorship W3132085485A5038092151 @default.
• W3132085485 hasAuthorship W3132085485A5043150762 @default.
• W3132085485 hasAuthorship W3132085485A5046151881 @default.
• W3132085485 hasAuthorship W3132085485A5051629490 @default.
• W3132085485 hasAuthorship W3132085485A5053495453 @default.
• W3132085485 hasAuthorship W3132085485A5056505692 @default.
• W3132085485 hasAuthorship W3132085485A5057566178 @default.
• W3132085485 hasAuthorship W3132085485A5058756575 @default.
• W3132085485 hasAuthorship W3132085485A5065435228 @default.
• W3132085485 hasAuthorship W3132085485A5069401956 @default.
• W3132085485 hasAuthorship W3132085485A5074364623 @default.
• W3132085485 hasAuthorship W3132085485A5075498749 @default.
• W3132085485 hasAuthorship W3132085485A5076440721 @default.
• W3132085485 hasAuthorship W3132085485A5082719961 @default.
• W3132085485 hasAuthorship W3132085485A5085819010 @default.
• W3132085485 hasAuthorship W3132085485A5087646089 @default.
• W3132085485 hasAuthorship W3132085485A5089861374 @default.
• W3132085485 hasAuthorship W3132085485A5090226538 @default.
• W3132085485 hasConcept C121608353 @default.
• W3132085485 hasConcept C126322002 @default.
• W3132085485 hasConcept C141071460 @default.
• W3132085485 hasConcept C142724271 @default.
• W3132085485 hasConcept C143998085 @default.
• W3132085485 hasConcept C203092338 @default.
• W3132085485 hasConcept C204787440 @default.
• W3132085485 hasConcept C207103383 @default.
• W3132085485 hasConcept C27081682 @default.
• W3132085485 hasConcept C2775930923 @default.
• W3132085485 hasConcept C2776694085 @default.
• W3132085485 hasConcept C2777292972 @default.
• W3132085485 hasConcept C2780739268 @default.
• W3132085485 hasConcept C2908647359 @default.
• W3132085485 hasConcept C31760486 @default.
• W3132085485 hasConcept C44249647 @default.
• W3132085485 hasConcept C530470458 @default.
• W3132085485 hasConcept C535046627 @default.
• W3132085485 hasConcept C71924100 @default.
• W3132085485 hasConcept C90924648 @default.
• W3132085485 hasConcept C99454951 @default.
• W3132085485 hasConceptScore W3132085485C121608353 @default.
• W3132085485 hasConceptScore W3132085485C126322002 @default.
• W3132085485 hasConceptScore W3132085485C141071460 @default.
• W3132085485 hasConceptScore W3132085485C142724271 @default.
• W3132085485 hasConceptScore W3132085485C143998085 @default.
• W3132085485 hasConceptScore W3132085485C203092338 @default.

• next